The Galleri blood test claims to detect cancer. However, it does not show signs of high precision, but it is promising.

Progress in reducing the global impact of cancer is slow, but the Galleri blood test, developed by the American company Grail, has sparked hope. It can detect signals from 50 types of cancer, with a correct identification rate of 62% for individuals with positive results and a specificity of 99.6% for those without cancer. However, 38% of positive results are false alarms, and the sensitivity of the test is only 40.4%, meaning that many cases of cancer could be missed. Although the test could become a useful tool in future screening programs, its high cost and the lack of evidence that its widespread use reduces cancer mortality are important considerations. In conclusion, although preliminary data is promising, the Galleri test is not a complete solution.